Cytokine Storm Syndrome

Area of Science:

• Immunology
• Pathology
• Genetics

Background:

• Cytokine storm syndrome (CSS) is a severe, often fatal hyperinflammatory condition.
• CSS encompasses conditions like familial and secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).
• The COVID-19 pandemic has increased focus on CSS due to its frequent occurrence and severity.

Purpose of the Study:

• To review the classification, diagnosis, and treatment of Cytokine Storm Syndrome (CSS).
• To highlight the genetic underpinnings of familial HLH and immune cell dysfunction in secondary HLH/MAS.
• To discuss evolving therapeutic strategies for CSS, including targeted anticytokine approaches.

Main Methods:

• Review of existing literature on Cytokine Storm Syndrome (CSS) classification and diagnostics.
• Analysis of genetic defects in familial hemophagocytic lymphohistiocytosis (HLH) and immune cell dysfunction in related syndromes.
• Evaluation of current and emerging therapeutic interventions for CSS, HLH, and MAS.

Main Results:

• Familial HLH stems from genetic defects in cytotoxic pathways (perforin).
• NK cell dysfunction is common in secondary HLH and MAS.
• Standard treatments like etoposide and glucocorticoids are being complemented by targeted anticytokine therapies (anti-IL-1, anti-IL-6).

Conclusions:

• Cytokine storm syndrome (CSS) presents diverse hyperinflammatory conditions requiring precise diagnosis.
• Genetic factors play a crucial role in familial HLH and contribute to secondary forms.
• Targeted anticytokine therapies represent a promising, safer alternative for managing CSS and related disorders.